Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2/3 RANDOMIZED, MULTICENTER STUDY OF OSIVELOTOR ADMINISTERED ORALLY TO ADULT AND ADOLESCENT PARTICIPANTS WITH SICKLE CELL DISEASE

NCT05431088 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05431088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2/3 RANDOMIZED, MULTICENTER STUDY OF OSIVELOTOR ADMINISTERED ORALLY TO ADULT AND ADOLESCENT PARTICIPANTS WITH SICKLE CELL DISEASE
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 22, 2022
Completion date
December 31, 2032
Enrollment
389 (estimated)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease